Andrew Arno - Aug 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Director
Signature
/s/ Andrew Arno
Stock symbol
OCX
Transactions as of
Aug 15, 2022
Transactions value $
$144,121
Form type
4
Date filed
8/17/2022, 08:15 PM
Previous filing
Jul 19, 2022
Next filing
Aug 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Award $0 +10K +8.19% $0.00 132K Aug 15, 2022 Direct F1
transaction OCX Common Stock, no par value Purchase $32.1K +34.5K +26.11% $0.93 167K Aug 15, 2022 Direct F2
transaction OCX Common Stock, no par value Purchase $112K +116K +69.37% $0.97 282K Aug 16, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +45K $0.00 45K Aug 15, 2022 Common Stock 45K $0.97 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
F2 The price of $0.93 per share represents a weighted average of prices ranging from $0.90 to $0.95 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price of $0.97 per share represents a weighted average of prices ranging from $0.93 to $1.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.